1 1

LuciTala 1 (Talazoparib) ЛюциТала 1 (талазопариб)

LuciTala 1 (Talazoparib) ЛюциТала 1 (талазопариб)

Brand Name: LuciTala 1
Origin: As stated on the specific product packaging
Small Orders: Subject to supplier availability
Tags: #LuciTala1 #Talazoparib #PARPInhibitor #PARPInhibitorTherapy #BreastCancer #ProstateCancer #HER2Negative #BRCA #BRCAMutation #HRRMutation #Oncology #CancerTreatment #TargetedTherapy #AnticancerMedicine #PrescriptionMedicine #PrecisionMedicine
View full details
  • Details
  • Description
Strength: 1 mg
Composition: Talazoparib 1 mg
Treatment: Used for certain adults with HER2-negative locally advanced or metastatic breast cancer with a deleterious or suspected deleterious germline BRCA mutation; talazoparib is also used in combination with enzalutamide for certain patients with advanced prostate cancer, according to applicable product labeling
Form: Capsules
Brand: LuciTala 1
Quantity Unit: Capsule
Manufacturer: Lucius Pharmaceuticals (verify against the specific product packaging)

LuciTala 1 (Talazoparib) is an oral targeted anticancer medicine containing talazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor.

Indications: Talazoparib is used for the treatment of certain adults with HER2-negative locally advanced or metastatic breast cancer with a deleterious or suspected deleterious germline BRCA mutation. It may also be used in combination with enzalutamide for certain adults with metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) gene alterations, depending on the applicable product labeling.

Mechanism of action: Talazoparib inhibits PARP enzymes and traps PARP on DNA, interfering with DNA repair and leading to cancer-cell death, particularly in tumors with defects in homologous recombination DNA repair.

Dosage form: Capsules for oral administration.

Administration: Taken orally once daily according to the prescribed treatment regimen. The dose may require adjustment based on kidney function, adverse reactions, or concomitant treatment.

Possible adverse effects: Common adverse reactions include anemia, neutropenia, thrombocytopenia, fatigue, nausea, headache, and decreased appetite. Serious risks may include myelosuppression and, rarely, myelodysplastic syndrome or acute myeloid leukemia.

Important: Talazoparib is a prescription oncology medicine and should be used under the supervision of a qualified healthcare professional.

Everyone Deserves Access to Life-saving Treatment Of Cancer. We are a Trusted Cancer Medicine seller delivering certified medications to every corner of the world.